Study Summary
This trialassesses the safety, effectiveness and side effects of a new oral cancer drug, TACH101, for people with advanced or metastatic solid tumors.
- Solid Metastatic Tumor
- Solid Tumors
- Advanced Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
5 Primary · 31 Secondary · Reporting Duration: Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length = 28 days)
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Phase 1a: Dose Escalation
1 of 3
Phase 1b: Dose Expansion
1 of 3
Phase 1: Dose Escalation
1 of 3
Experimental Treatment
70 Total Participants · 3 Treatment Groups
Primary Treatment: Phase 1a: Dose Escalation · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has the FDA granted sanction to Phase 1a: Dose Escalation?
"Our experts at Power rated the safety rating of Phase 1a: Dose Escalation as a 1 due to its status as a Phase 1 trial, indicating that there is only sparse evidence confirming efficacy and limited data backing its safety." - Anonymous Online Contributor
How many participants are included in this experiment?
"Affirmative. According to clinicaltrials.gov, this trial is in the process of selecting participants. It was posted on January 19th 2023 and most recently edited on January 25th 2023, with a need for 70 volunteers from one medical site." - Anonymous Online Contributor
Are there any open opportunities for participants to join this clinical investigation?
"Affirmative. The clinicaltrials.gov database reveals that this research is currently in need of volunteers. It was initially posted on January 19th 2023 and recently revised on the 25th of the same month. 70 individuals have to be recruited from just one trial site." - Anonymous Online Contributor